Abstract: The present description concerns a memory device (200) including a non-volatile memory circuit (101); a buffer memory circuit (203) comprising a volatile memory circuit (221); an input-output circuit (105); a first data link (104) coupling the non-volatile memory circuit (101) to the buffer memory circuit (203); a second data link (106) coupling the buffer memory circuit (203) to the input-output circuit (105); and a control circuit (225), wherein the buffer memory circuit (203) is adapted to implementing calculations having as operands data stored in the volatile memory circuit (221).

Abstract: Novel anti-human CD25 antibodies or antigen-binding fragments thereof and their use for treating cancer and infectious diseases. Also, a nucleic acid encoding an anti-human CD25 antibody or antigen-binding fragment thereof, and a fusion protein including an isolated anti-human CD25 antibody or antigen-binding fragment thereof. Further, a pharmaceutical composition including an isolated anti-human CD25 antibody or antigen-binding fragment thereof.

Abstract: Novel anti-human CD25 antibodies and their use for treating cancer and infectious diseases. Also, a nucleic acid encoding an anti-human CD25 antibody or an antigen-binding fragment thereof, and a fusion protein including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof. Further, a pharmaceutical composition including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof.

Abstract: A percutaneous bypass method for implanting a bypass graft between two vessels is described. The bypass graft comprises a first part and a second part, each having a tubular shape and comprising respective lumens. The method comprises the step of inserting a second sheath, from the outside to the inside of a bypass portion of the first part, through a puncture therein, and retracting the second sheath so as to deploy and implant a hook portion of the second part into the second vessel, and deploy a bypass portion of the second part outside the second vessel, from the second vessel to the first part, and within the lumen of the first part.

Abstract: A memory cell, includes first and second main terminals, an auxiliary terminal; M memristor(s) between the main terminals, M?1; M primary switch(es), each in parallel with a memristor; and a secondary switch between the second main terminal and the auxiliary terminal. It is configured for writing to at least one memristor by opening each primary switch in parallel with the at least one memristor, closing each other primary switch, closing the secondary switch and applying a corresponding programming voltage between the first main terminal and the auxiliary terminal; and for reading at least one memristor by opening each primary switch in parallel with the at least one memristor, closing each other possible primary switch, opening the secondary switch and measuring a corresponding electrical quantity between the main terminals.

Abstract: The use of UV-activated Copper Radical Oxidase (CRO) enzymes in the implementation of oxidation reactions. Also, a process for oxidizing organic compounds using enzymes which are activated by UV light. The process also leads to concomitant formation of hydrogen peroxide, that can optionally be used in hydrogen peroxide mediated processes. Further, the process relates to the oxidation of alcohols in aldehydes.

Abstract: A system is described for emitting a radiofrequency field for a magnetic resonance imaging device, including a volumetric antenna that emits a radiofrequency field, a device for homogenizing the radiofrequency field arranged between said volume antenna and a part of the body to be imaged. The device may include a first continuous metal track with an overall length of approximately 0.5 to approximately 1.5 times said wavelength of the radio frequency field. The first metallic track may occupy a surface with a largest dimension ranging between approximately 5% and approximately 15% of said wavelength of the radio frequency field. The first metal track is arranged in a pattern including a plane of symmetry that is normal to the electrical component of the radio frequency field, so as to give the device an electric dipole property including a natural frequency strictly greater than the frequency of the radio frequency field.

Abstract: Memory devices such as phase change memory (PCM) devices utilizing Ovonic Threshold Switching (OTS) selectors may be used to fill the gap between dynamic random-access memory (DRAM) and mass storage and may be incorporated in high-end microcontrollers. Since the programming efficiency and reading phase efficiency of such devices is directly linked to the leakage current of the OTS selector as well as sneak-path management, a sense amplifier disclosed herein generates an auto-reference that takes into account the leakage currents of unselected cells and includes a regulation loop to compensate for voltage drop due to read current sensing. This auto-referenced sense amplifier, built utilizing the principle of charge-sharing, may be designed on a 28 nm fully depleted silicon-on-insulator (FDSOI) technology, provides robust performance for a wide range of sneak-path currents and consequently for a large range of memory array sizes, and is therefore suitable for use in embedded memory in high-end microcontroller.

Abstract: The present invention relates to a conjugated compound comprising a marker M pharmaceutically acceptable, and a peptide or pseudo-peptide P having at most 30 amino acid residues and able to bind the Low-Density Lipoprotein Receptor (LDLR) and to its use in a method of labelling and/or detecting and/or treating cancerous cells in a subject by administration of the conjugated compound to the subject an analysis of the presence and/or the amount of marker.

Abstract: The present invention relates the field of CMV and CMV related diseases. Using a powerful rat model of CMV infection of the embryonic brain, the inventors have looked for the existence of postnatal neurological and neurosensory manifestations, and have tested whether the early pharmacological targeting of microglia during pregnancy impacts on postnatal phenotypes. Particularly, the inventors tested the clodronate and the doxycycline and showed that these compounds improve the postnatal outcome of the baby. Thus, the invention relates to a compound which modifies the microglia for use in the treatment of CMV related diseases in a subject in need thereof.

Abstract: The method for inferring epileptogenicity of a brain region not observed as recruited or not observed as not recruited, in a seizure activity of an epileptic patient brain, includes: providing a computerized model modelling various regions of a primate brain and connectivity between the regions; providing the computerized model with a model able to reproduce an epileptic seizure dynamic in the primate brain; providing structural data of the epileptic patient brain and personalizing the computerized model using the structural data to obtain a virtual epileptic patient (VEP) brain model; translating a state-space representation of the VEP brain model into a probabilistic programming language (PPL) using probabilistic state transitions to obtain a probabilistic virtual epileptic patient brain model (BVEP); and acquiring electro- or magneto-encephalographic data of the patient brain and fitting the probabilistic VEP brain model against the data to infer the epileptogenicity of the brain region that is not observe

Abstract: Chemoenzymatic process for coproducing a disulfide and a sulfoxide or a sulfone The present invention relates to a chemoenzymatic process for coproducing disulfide and sulfoxide or sulfone from a composition M comprising: 1) a sulfide, 2) optionally an oxidizing agent, 3) an organic compound bearing at least one thiol group, 4) an enzyme E catalyzing the oxidation of said sulfide to sulfoxide or to sulfone, 5) an enzyme D catalyzing the formation of a disulfide bridge between two equivalents of said organic compound bearing at least one thiol group to form a dimer, and 6) a cofactor common to the two enzymes E and D; and also to a composition enabling especially the implementation of this process. The present invention also relates to the use of a mercaptan for reducing a disulfide bridge formed between two equivalents of an organic compound bearing at least one thiol group, and more particularly to the use thereof as regeneration substrate of the process described above.

Abstract: A seismic wave shield for protecting an area from seismic vibrations and a method of shielding an area from seismic waves by installing a seismic wave shield. The seismic wave shield comprises a set of columns embedded in regolith and in contact with bedrock. There is a material contrast between a material forming the columns and the regolith.

Abstract: The present invention relates to an apheresis column loaded with a solid support comprising a composition comprising at least one peptide selected from the group consisting of: —the ?I7I-I85cit peptide of amino acid sequence VDIDIKIX1SCX2GSCS (SEQ ID NO: 8) wherein X1 and X2 each represent a citmllyl residue, —the ?62I-635Cit peptide of amino acid sequence X1GHAKSX2PVX3GIHTS (SEQ ID NO: 12) wherein X1, X2 and X3 each represent a citmllyl residue—the P60-74cit-NH2 peptide of amino acid sequence X1PAPPPISGGGYX2AX3 (SEQ ID NO: 15) wherein X1 and X2 each represent a citmllyl residue and X3 represents a citmllyl derivative with a carboxamide group and—the peptide, referred to as the Ac-a36-50crt peptide, having the amino acid sequence GPX1VVEX2HQSACKDS (SEQ ID NO: 6) wherein the residue G at the N-terminal is acetylated and wherein X1 and X2 each represent a citmllyl residue and/or the a36-50cit peptide of amino acid sequence GPX1VVEX2HQSACKDS (SEQ ID NO: 5) wherein X1 and X2 each represent a citmllyl residue.

Abstract: The present invention relates to regulatory T cell and uses thereof. By their immunosuppressive and anti-inflammatory activities, regulatory T cells play a central role in peripheral tolerance and thus critically prevent the development of autoimmune and inflammatory disorders. The inventors showed that Foxp3+CD4+ Tregs express high levels of LT?, which negatively regulates their immunosuppressive signature. They demonstrated that the adoptive transfer of LT??/? Tregs in mice protects from dextran sodium sulfate (DSS)-induced colitis and attenuates inflammatory bowel disease (IBD), multi-organ autoimmunity and the development of CAC. The inventors also showed that by mixed bone marrow chimeras that LT? expression specifically in hematopoietic cells negatively controls the immunosuppressive signature of Tregs. In particular, the present invention relates to regulatory T cell characterized in that it does not express or expresses reduced levels of lymphotoxin alpha.

Abstract: The present invention relates to a neuromorphic circuit suitable for implementing a neural network, the neuromorphic circuit comprising: lines of words, pairs of complementary bit-lines, source lines, a set of elementary cells, an electronic circuit implementing a neurone having an output and including: a set of logic components, a counting unit, a comparison unit comprising a comparator and a comparison voltage generator, the comparator being suitable for comparing the output of the counting unit with the comparison voltage generated by the comparison voltage generator in order to output a signal dependent on the comparison and corresponding to the output of the electronic circuit which implements a neurone.

Abstract: Sarcomas are rare malignant tumors arising from the mesenchymal tissues at all body sites. The inventors show that in a mouse model of p16/p19 deficiency prone to tumor development, the absence of the mouse pantetheinase Vnn1 enhances the frequency of aggressive fibrosarcomas. They also show that reintroduction of a catalytically active form of the Vnn1 pantetheinase limits tumor growth in vivo. Interestingly, VNN1 expression in human sarcomas is associated with reduced aggressiveness and lower risk of metastatic relapse in patients. In conclusion, Vnn1 represents a novel marker of sarcoma and may modulate tumor aggressiveness by sustaining myofibroblast cell differentiation, thereby limiting evolution towards undifferentiated tumors. The present invention relates to the use of Vnn1 as a biomarker and a therapeutic target in sarcomas.

Abstract: The present invention relates to antibodies having specificity for BTN2 and uses thereof, in particular for the treatment of cancer.

Abstract: The method of optimizing an intracranial implantation scheme of a set of electroencephalographic electrodes for identification of an epileptogenic zone in an epileptic patient’s brain includes: - providing a model of the epileptogenic zone and a model of the propagation of an epileptic discharge from the epileptic zone to a propagation zone, and loading the models in a computerized platform personalized according to the patient’s brain; - providing at least one hypothesis of the localization of the epileptogenic zone in the patient brain; - for the at least hypothesis of the localization of the epileptogenic zone, simulating, in the personalized computerized patient’s brain, epileptic seizures, and determining, for the hypothesis and epileptic seizures, a network of propagation zones; - for a plurality of intracranial implantation schemes of the electroencephalographic electrodes, obtaining, using the personalized computerized patient’s brain, simulated electroencephalographic signals activity to be measured

Abstract: A method for functionalizing a surface of a dielectric plate that is transparent to visible light—to be able to examine the dielectric plate using optical microscopy—includes depositing a negative film on the dielectric slide. The negative film comprises a polymerizable composition that polymerizes when exposed to an electron beam. The polymerizable composition is polymerized—by exposing the negative film to the electronic beam—at a set of points representing a preset pattern. Non-polymerized portions of the polymerizable composition are dissolved—to develop the negative film—forming a set of pads of polymerized portions of the polymerizable composition. Each pad corresponds to one point of the preset pattern. A metal film is disposed on the negative film, and the developed negative film is dissolved to define holes through the metal film. Each of the holes corresponds to a base of one pad of the set of pads.